Your browser doesn't support javascript.
loading
Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial.
Pucciarelli, Salvatore; De Paoli, Antonino; Guerrieri, Mario; La Torre, Giuseppe; Maretto, Isacco; De Marchi, Francesco; Mantello, Giovanna; Gambacorta, Maria Antonietta; Canzonieri, Vincenzo; Nitti, Donato; Valentini, Vincenzo; Coco, Claudio.
Afiliação
  • Pucciarelli S; 1Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy 2Department of Radiation Oncology, National Cancer Institute, Aviano, Italy 3General Surgery, University Politecnica delle Marche, Ancona, Italy 4Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy 5Department of Surgical Oncology, National Cancer Institute, Aviano, Italy 6Department of Radiotherapy, State Hospital, Ancona, Italy 7Department of Radiotherapy, Catholic
Dis Colon Rectum ; 56(12): 1349-56, 2013 Dec.
Article em En | MEDLINE | ID: mdl-24201388
BACKGROUND: Transanal local excision has been suggested as an attractive approach for patients with rectal cancer who show a major clinical response after preoperative chemoradiotherapy. OBJECTIVE: To evaluate the impact of transanal local excision on the local recurrence of rectal cancer in patients who had a major clinical response after preoperative chemoradiotherapy. DESIGN: Sequential 2-stage phase II study for early efficacy. SETTING: Multicenter study. PATIENTS: Patients with clinical T3 or low-lying T2 rectal adenocarcinoma that showed a major clinical response after a preoperative chemoradiotherapy. Eligible patients underwent a full-thickness transanal local excision. According to their histopathology, the patients staged as ypT0-1 were observed, while the remaining patients were recommended to undergo a subsequent total mesorectal excision. MAIN OUTCOME MEASURES: A local recurrence rate of ≤5% was set as a successful rate for stopping the trial early after the first stage. RESULTS: The study group included 63 patients. Before chemoradiotherapy, patients were staged as clinical T3 (n = 42) and T2 (n = 21). After the local excision, 43 patients fulfilled the criteria to be observed with no further treatment. Nine of the remaining 20 patients for whom a subsequent total mesorectal excision was recommended refused surgery. Two of these patients who refused surgery had intraluminal local recurrence; both had a ypT2 tumor and underwent salvage surgery. The estimated cumulative 3-year overall survival, disease-free survival and local disease-free survival were 91.5% (95% CI: 75.9-97.2), 91.0% (95% CI: 77.0-96.6) and 96.9% (95% CI: 80.3-99.5), respectively. LIMITATIONS: The time of follow-up is still short and the sample size is limited. CONCLUSIONS: Our data suggest that local excision is a good option for patients with a major clinical response after chemoradiotherapy. A longer period of follow-up is required to confirm these findings.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Adenocarcinoma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Adenocarcinoma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2013 Tipo de documento: Article